Cronos Group Operating Expenses 2017-2025 | CRON

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cronos Group operating expenses from 2017 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cronos Group operating expenses from 2017 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$67.7B
Zoetis (ZTS)	$65.3B
Daiichi Sankyo, - (DSNKY)	$46.2B
Takeda Pharmaceutical (TAK)	$45.9B
BeOne Medicines - (ONC)	$31.6B
Sandoz Group AG (SDZNY)	$25.8B
Summit Therapeutics (SMMT)	$21.3B
Merck (MKKGY)	$16.4B
Shionogi (SGIOY)	$15.2B
United Therapeutics (UTHR)	$13.6B
Neurocrine Biosciences (NBIX)	$12.4B
Orion OYJ (ORINY)	$10.8B
IPSEN (IPSEY)	$10.4B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Corcept Therapeutics (CORT)	$7.6B
Grifols, S.A (GRFS)	$7.3B
Stevanato Group S.p.A (STVN)	$7.2B
Ionis Pharmaceuticals (IONS)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Crinetics Pharmaceuticals (CRNX)	$2.5B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B
Endo (NDOI)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.7B